Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study

Authors: BONNY, C.¹; FONTAINE, H.²; POYNARD, T.³; HÉZODE, C.⁴; LARREY, D.⁵; MARCELLIN, P.⁶; BOURLIÈRE, M.⁷; BRONOWICKI, J. P.⁸; MERLE, P.⁹; ZARSKI, J. P.¹⁰; SAPEY, T.¹¹; GUILLEMARD, C.¹²; UGHETTO, S.¹³; HENQUELL, C.¹⁴; NICOLAS, C.¹; ROCHE, C.¹; RANDL, K.¹; BOMMELAER, G.¹; ABERGEL, A.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 24, Number 4, August 2006 , pp. 593-600(8)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Summary Aim

To assess the rate of sustained virological response in naïve hepatitis C virus-type 5 patients treated by standard interferon or percutaneous endoscopic gastrostomy-interferon (peg-interferon) and ribavirin combination for 48 weeks. Patients and methods

A total of 87 hepatitis C virus patients were included from 12 centres in France; 28 patients received interferon plus ribavirin and 59 were treated with peg-interferon plus ribavirin. Results

Baseline characteristics were: mean age 58 ± 11 years, sex ratio 1, 66% had metavir fibrosis score ≥F2, 21% were cirrhotics and 53% had pretherapeutic viral load ≥800 000 IU/mL. Sustained virological response was achieved in 64% and 58% of hepatitis C virus-5 patients treated with interferon and peg-interferon, respectively (NS). In adherent patients, sustained virological response was obtained in 75% of patients. Sustained virological response in hepatitis C virus-5 patients (60%) was significantly higher than sustained virological response in hepatitis C virus-1 patients (37%) (P = 0.0499) and not significantly different from sustained virological response in hepatitis C virus-2-3 patients (63%) (P = 0.8098). Conclusions

Combination therapy is effective in 60% of hepatitis C virus-5-infected patients. Sustained virological response seems better in hepatitis C virus-5 patients than in hepatitis C virus-1 patients, and is similar to that of hepatitis C virus-2-3 patients. More studies are needed to determine optimal duration of treatment in hepatitis C virus-5 patients.

Document Type: Research article

DOI: 10.1111/j.1365-2036.2006.03018.x

Affiliations: 1: Service d'Hépato-Gastroentérologie, Hôtel-Dieu, Clermont-Ferrand 2: Service d'Hépatologie, Hôpital Necker 3: Service d'Hépato-Gastroentérologie, Hôpital La Pitié Salpetrière, Paris 4: Service d'Hépatologie, Hôpital Henri Mondor, Créteil 5: Service d'Hépato-Gastroentérologie, CHU de Montpellier 6: Service d'Hépato-Gastroentérologie, Hôpital Beaujon, Paris 7: Service d'Hépato-Gastroentérologie, Hôpital Saint-Joseph, Marseille 8: Service d'Hépato-Gastroentérologie, CHU de Nancy 9: Service d'Hépato-Gastroentérologie, Hôpital Edouard Herriot, Lyon 10: Service d'Hépato-Gastroentérologie, CHU de Grenoble 11: Service d'Hépato-Gastroentérologie, CHR de Châteauroux 12: Service d'Hépato-Gastroentérologie, CHU de Caen 13: Service d'Epidémiologie, Hôtel-Dieu, Clermont-Ferrand 14: Service de Virologie, Faculté de Médecine, Clermont-Ferrand, France

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.